IDEX Biometrics Interim Report as of 30 September 2022
Oslo, Norway – 10 November 2022 - IDEX Biometrics ASA’s interim report as of September 30, 2022 is enclosed with this notice.
A webcast presentation will be held by Vince Graziani, Chief Executive Officer, today at 09:00 CET. The webcast presentation can be viewed at the following link: https://tinyurl.com/5t53tser
The interim report and the presentation to be used in the webcast are available on the IDEX Biometrics website: www.idexbiometrics.com/investors/interim-results/
2022 has become a year of broad-based commercialization for biometric smart cards. In our primary target market, many banks have begun, or are planning, launches and commercialization of biometric payment cards. During the year, the rapidly increasing demand for cyber security, digital authentication, and crypto currency cold wallet solutions has sparked a wave of new applications and use cases for biometric smart cards.
In the payments space, we expect to have a total of 10 launches this year, or by early 2023, from banks and issuers together with card-maker IDEMIA and customers of our channel partner, Zwipe. Seven new launches are anticipated for the fourth quarter of 2022. So far this year, three launches have been announced.
We now have 9 design wins with card makers for our Infineon SLC38 reference platform and Turnkey Solution. During the quarter, six of these card makers have already placed initial orders for IDEX sensors. We also continue to see rapidly increasing demand for IDEX biometric security solutions for use in digital authentication, cyber security, and digital HASHwallets, to facilitate adoption of Web3 and digital assets.
In September we held a capital markets day in Oslo with several of our partners attending. The presentations from management outlined a clear roadmap and a path to commercial acceleration during 2023 and beyond. Our panel discussion with partners IDEMIA, Rocker and eSignus focused on the commercial traction, and market adoption for biometric cards. These market mega trends for both payments and digital authentication represent a massive market opportunity for IDEX biometric solutions over one-to-five-year horizon.
Third Quarter Financial Performance
For the third quarter ended September 30, 2022, the Company recorded consolidated revenue of $928 thousand. Sequentially, third quarter revenue decreased approximately 16% from the second quarter of 2022, reflecting the timing of shipments to our two largest customers in the payment card segment. By comparison, third quarter 2021 revenue was $732 thousand, for a year-over-year quarterly increase of 27%.
Gross profit margin, as a percentage of revenue, was approximately 12% for the third quarter of 2022, compared sequentially to approximately 7% in the second quarter of 2022. For the third quarter of 2021, a similarly calculated gross profit margin was approximately 59%, with the higher figure reflecting sales mix. The lower margins in 2022 reflect a shift in mix to lower margin payment card products and higher costs of wafers, assembly services, and certain components, as well as the write-off of previous-generation products held in inventory.
Net loss for the third quarter of 2022 totaled ($9.0 million), representing a loss per share of ($0.01), in contrast to a net loss of ($7.5 million) for the third quarter of 2021, representing a loss per share of ($0.01), and a net loss of ($9.2 million) for the second quarter of 2022, representing a loss per share of ($0.01).
The company’s cash balance totaled $9.1 million as of September 30, 2022, in contrast to $12.9 million as of September 30, 2021, and $33.8 million as of December 31, 2021.
For further information contact:
Marianne Bøe, Head of Investor Relations
Tel: + 47 918 00186
About IDEX Biometrics
IDEX Biometrics (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal authentication for all. We help people make payments, prove their identity, gain access to information or unlock devices with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com
IDEX, IDEX Biometrics and the IDEX logo are trademarks owned by IDEX Biometrics ASA. All other brands or product names are the property of their respective holders.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Power Purchase Agreements signed under South Africa’s REIPPPP Bid Window 58.12.2022 10:49:54 CET | Press release
Oslo / Cape Town, 8 December 2022: Today, Scatec ASA, a leading renewable energy provider in emerging markets, signed power purchase and implementation agreements (Legal Close) for the three solar Grootfontein projects in the Western Cape Province of South Africa, under the Renewable Energy Independent Power Producer Procurement Programme (REIPPPP), alongside the South African government. “We are proud to have reached this milestone in the procurement process - and are excited to continue delivering clean and reliable energy in South Africa. The South African government has shown strong commitment to deliver in challenging times - and today’s achievement is a testament to the hard work and dedication of actors in the country’s renewable energy transition. Scatec continues to drive action and remains the leading solar IPP in the country and continent. We look forward to completing the necessary deliverables in the new year.” says Scatec Executive Vice President for Sub-Saharan Africa, J
Savosolar appoints Kirsi Suopelto as Vice President, Strategy8.12.2022 10:30:00 CET | Press release
Savosolar Plc Company Announcement 8 December 2022 at 10.30 a.m. (CET) Savosolar appoints Kirsi Suopelto as Vice President, Strategy Savosolar has appointed Ms. Kirsi Suopelto, Master of Laws and MBA (born 1976) as Vice President, Strategy of Savosolar Plc and a member of the group's executive management team. Kirsi's tasks include preparation of large investments and financial arrangements as well as M&A projects. Kirsi was elected as the chairperson of the board of Savosolar Plc at the extraordinary general meeting held on November 25, 2022 and at the subsequent organizational meeting of the board. Kirsi has more than 20 years of experience in the financial industry, both in legal and commercial positions. Kirsi has worked for several companies offering financial services in Finland and abroad. She has also been promoting financial industry interests. Kirsi is the chairperson of the board, owner and founder of Hybrid Consulting Oy, which acted as an advisor to VG-Shipping Oy and Meri
Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis8.12.2022 10:12:00 CET | Press release
8 December 2022 Clinigen notesresults from the MIROCALS trial investigating low doseProleukin® (aldesleukin)in patients withamyotrophic lateral sclerosis Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, is pleased to notethe announcement of top-line results from MIROCALS (Modifying Immune Response & OutComes in Amyotrophic Lateral Sclerosis) a phase 2b randomised placebo-controlled trial investigating the efficacy and safety of low dose interleukin-2 (ld IL-2) for controlling neuro-inflammation in newly-diagnosed patients with amyotrophic lateral sclerosis (ALS). The MIROCALS trial, conducted in 220 patients from 17 clinics across the UK and France, in collaboration with eight leading research groups in the UK, France, Italy and Sweden, investigated whether low dose IL-2 can modify aspects of neuro- inflammation, which is believed to play a central role in ALS disease progression. Dr. Gilbert Bensimon presented the top-line results at the International Symposi
Kvika banki hf.: Birkir Jóhannsson new CEO of TM8.12.2022 10:01:44 CET | Press release
Birkir Jóhannsson has been appointed CEO of TM, Kvika banki‘s subsidiary. Birkir will be replacing Sigurður Viðarsson as he takes up the position of deputy CEO at Kvika. Birkir has in past years worked as managing director of core operations and digital solutions at VIS Insurance and has substantial work experience within banking, payment solutions and finance. Birkir has previously been employed at Birti Capital Partners, Valitor, Arion bank and Attorneys atHöfðabakki.. Birkir holds a law degree from the University of Iceland and a master’s degree in corporate finance from Reykjavik University. In addition, Birkir has completed a degree in securities trading and is licensed as a district court attorney. Birkir will be a member of the Kvika group management board. When the changes, that Kvika banki introduced on 5 December, have been implemented the Kvika group management team will consist of Kvika banki’s management board, the CEO of TM, the CEO of Kvika asset management and the CEO o
EV-Joyment, Emotional Promise Motivate EV Adoption Over Environmental Benefits8.12.2022 10:00:58 CET | Press release
Latest Escalent EVForward™ Europe report findings encourage brands to tap into emotional aspirations of BEV ownership to engage with consumers LIVONIA, Mich., Dec. 08, 2022 (GLOBE NEWSWIRE) -- As new-car buyer personas continue to evolve, connecting with consumers’ emotions and personality is more likely to ignite interest in battery electric vehicles (BEVs). This diverges from the long-standing industry narrative that environmental benefits are what drive BEV adoption, creating great opportunity for brands to expand their messaging and embrace new customers with a varying mix of values, lifestyles and attitudes. The environmental and running cost credentials of BEVs are clear, but relatively few car buyers are motivated by such a narrow range of rational criteria. In 2022, 43% of car buyers acknowledge the environmental credentials of BEVs as a benefit, but the same factor only ranks 9th out of 19 in a hierarchy of most important car buying criteria, thus revealing the environment’s l